Concise review: Humanized models of tumor immunology in the 21st century: Convergence of cancer research and tissue engineering

Stem Cells

Volumn 33, Issue 6, 2015, Pages 1696-1704

  Holzapfel, Boris Michael ^a,b   Wagner, Ferdinand ^a,c   Thibaudeau, Laure ^a   Levesque, Jean Pierre ^d   Hutmacher, Dietmar Werner ^a,e,f  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adult hematopoietic stem cells; Adult stem cells; Bone; Bone marrow; CD34+; Humanized mice models; Stem cell transplantation; Stem cell microenvironment interactions; Tissue regeneration

Indexed keywords

ADAPTIVE IMMUNITY; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EXTRACELLULAR MATRIX; GENETIC ENGINEERING; HUMORAL IMMUNITY; INNATE IMMUNITY; MONOLAYER CULTURE; MOUSE STRAIN; MURINE MODEL; NONHUMAN; REGENERATIVE MEDICINE; STEM CELL NICHE; TISSUE ENGINEERING; TUMOR CELL CULTURE; TUMOR ESCAPE; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; ANIMAL; DISEASE MODEL; HUMAN; NEOPLASMS; PROCEDURES; STEM CELL TRANSPLANTATION; TRANSLATIONAL RESEARCH;

ANIMALIA; MURINAE; MUS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASMS; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84929774215     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1978     Document Type: Article

References (92)

1. Couzin-Frankel J,. The littlest patient. Science 2014; 346: 24-27.
2. Holzapfel BM, Thibaudeau L, Hesami P, et al., Humanised xenograft models of bone metastasis revisited: Novel insights into species-specific mechanisms of cancer cell osteotropism. Cancer Metastasis Rev 2013; 32: 129-145.
3. Thibaudeau L, Quent VM, Holzapfel BM, et al., Mimicking breast cancer-induced bone metastasis in vivo: Current transplantation models and advanced humanized strategies. Cancer Metastasis Rev 2014; 33: 721-735.
4. Perrin S,. Preclinical research: Make mouse studies work. Nature 2014; 507: 423-425.
5. Burkhardt AM, Zlotnik A,. Translating translational research: Mouse models of human disease. Cell Mol Immunol 2013; 10: 373-374.
6. Brehm MA, Shultz LD, Greiner DL,. Humanized mouse models to study human diseases. Curr Opin Endocrinol Diabetes Obes 2010; 17: 120-125.
7. Macchiarini F, Manz MG, Palucka AK, et al., Humanized mice: Are we there yet? J Exp Med 2005; 202: 1307-1311.
8. Shultz LD, Brehm MA, Garcia-Martinez JV, et al., Humanized mice for immune system investigation: Progress, promise and challenges. Nat Rev Immunol 2012; 12: 786-798.
9. Shultz LD, Ishikawa F, Greiner DL,. Humanized mice in translational biomedical research. Nat Rev Immunol 2007; 7: 118-130.
10. Davies G,. What is a humanized mouse? Remaking the species and spaces of translational medicine. Body Soc 2012; 18: 126-155.
11. Karpowicz P, Cohen CB, van der Kooy D,. It is ethical to transplant human stem cells into nonhuman embryos. Nat Med 2004; 10: 331-335.
12. Flanagan SP,. 'Nude', a new hairless gene with pleiotropic effects in the mouse. Genet Res 1966; 8: 295-309.
13. Ganick DJ, Sarnwick RD, Shahidi NT, et al., Inability of intravenously injected monocellular suspensions of human bone marrow to establish in the nude mouse. Int Arch Allergy Appl Immunol 1980; 62: 330-333.
14. Bosma GC, Custer RP, Bosma MJ,. A severe combined immunodeficiency mutation in the mouse. Nature 1983; 301: 527-530.
15. Lapidot T, Pflumio F, Doedens M, et al., Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice. Science 1992; 255: 1137-1141.
16. Mosier DE, Gulizia RJ, Baird SM, et al., Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988; 335: 256-259.
17. McCune JM, Namikawa R, Kaneshima H, et al., The SCID-hu mouse: Murine model for the analysis of human hematolymphoid differentiation and function. Science 1988; 241: 1632-1639.
18. Makino S, Kunimoto K, Muraoka Y, et al., Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 1980; 29: 1-13.
19. Shultz LD, Schweitzer PA, Christianson SW, et al., Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995; 154: 180-191.
20. Mombaerts P, Iacomini J, Johnson RS, et al., RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992; 68: 869-877.
21. Shinkai Y, Rathbun G, Lam KP, et al., RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992; 68: 855-867.
22. Banuelos SJ, Shultz LD, Greiner DL, et al., Rejection of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive human lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1(null) mice. Clin Immunol 2004; 112: 273-283.
23. Palucka AK, Gatlin J, Blanck JP, et al., Human dendritic cell subsets in NOD/SCID mice engrafted with CD34+ hematopoietic progenitors. Blood 2003; 102: 3302-3310.
24. Leonard WJ,. Cytokines and immunodeficiency diseases. Nat Rev Immunol 2001; 1: 200-208.
25. Goldman JP, Blundell MP, Lopes L, et al., Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol 1998; 103: 335-342.
26. Ito R, Takahashi T, Katano I, et al., Current advances in humanized mouse models. Cell Mol Immunol 2012; 9: 208-214.
27. Hiramatsu H, Nishikomori R, Heike T, et al., Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model. Blood 2003; 102: 873-880.
28. Traggiai E, Chicha L, Mazzucchelli L, et al., Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004; 304: 104-107.
29. Quintana E, Shackleton M, Sabel MS, et al., Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598.
30. Wege AK, Ernst W, Eckl J, et al., Humanized tumor mice-A new model to study and manipulate the immune response in advanced cancer therapy. Int J Cancer 2011; 129: 2194-2206.
31. Wulf-Goldenberg A, Eckert K, Fichtner I,. Intrahepatically transplanted human cord blood cells reduce SW480 tumor growth in the presence of bispecific EpCAM/CD3 antibody. Cytotherapy 2011; 13: 108-113.
32. Seitz G, Pfeiffer M, Fuchs J, et al., Establishment of a rhabdomyosarcoma xenograft model in human-adapted mice. Oncol Rep 2010; 24: 1067-1072.
33. Wege AK, Schmidt M, Ueberham E, et al., Co-transplantation of human hematopoietic stem cells and human breast cancer cells in NSG mice: A novel approach to generate tumor cell specific human antibodies. MAbs 2014; 6: 968-977.
34. King MA, Covassin L, Brehm MA, et al., Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol 2009; 157: 104-118.
35. Abate-Daga D, Lagisetty KH, Tran E, et al., A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther 2014; 25: 1003-1012.
36. Guichelaar T, Emmelot ME, Rozemuller H, et al., Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: A role for bone marrow stromal cells in neutralizing regulatory T cells. Clin Cancer Res 2013; 19: 1467-1475.
37. Ito A, Ishida T, Yano H, et al., Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother 2009; 58: 1195-1206.
38. McCormack E, Adams KJ, Hassan NJ, et al., Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother 2013; 62: 773-785.
39. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, et al., Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 2013; 19: 3153-3164.
40. Song DG, Ye Q, Carpenito C, et al., In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 2011; 71: 4617-4627.
41. Kloss CC, Condomines M, Cartellieri M, et al., Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013; 31: 71-75.
42. Markley JC, Sadelain M,. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 2010; 115: 3508-3519.
43. Abate-Daga D, Speiser DE, Chinnasamy N, et al., Development of a T cell receptor targeting an HLA-A 0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer. PLoS One 2014; 9: e93321.
44. Tanner A, Taylor SE, Decottignies W, et al., Humanized mice as a model to study human hematopoietic stem cell transplantation. Stem Cells Dev 2014; 23: 76-82.
45. Werner-Klein M, Proske J, Werno C, et al., Immune humanization of immunodeficient mice using diagnostic bone marrow aspirates from carcinoma patients. PLoS One 2014; 9: e97860.
46. Lang J, Weiss N, Freed BM, et al., Generation of hematopoietic humanized mice in the newborn BALB/c-Rag2null Il2rgammanull mouse model: A multivariable optimization approach. Clin Immunol 2011; 140: 102-116.
47. Legrand N, Weijer K, Spits H,. Experimental models to study development and function of the human immune system in vivo. J Immunol 2006; 176: 2053-2058.
48. Kikuchi K, Kondo M,. Developmental switch of mouse hematopoietic stem cells from fetal to adult type occurs in bone marrow after birth. Proc Natl Acad Sci USA 2006; 103: 17852-17857.
49. Tagawa M, Goto S, Takenaga K, et al., Reduced tumorigenicity of human gastric carcinoma cells engineered to produce IL-2 in SCID mice reconstituted with peripheral blood cells from cancer patients. Cancer Lett 1998; 123: 87-93.
50. Aspord C, Pedroza-Gonzalez A, Gallegos M, et al., Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 2007; 204: 1037-1047.
51. Ishikawa F, Yasukawa M, Lyons B, et al., Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 2005; 106: 1565-1573.
52. Brehm MA, Cuthbert A, Yang C, et al., Parameters for establishing humanized mouse models to study human immunity: Analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin Immunol 2010; 135: 84-98.
53. Onoe T, Kalscheuer H, Danzl N, et al., Human natural regulatory T cell development, suppressive function, and postthymic maturation in a humanized mouse model. J Immunol 2011; 187: 3895-3903.
54. Rongvaux A, Takizawa H, Strowig T, et al., Human hemato-lymphoid system mice: Current use and future potential for medicine. Annu Rev Immunol 2013; 31: 635-674.
55. Biswas S, Chang H, Sarkis PT, et al., Humoral immune responses in humanized BLT mice immunized with West Nile virus and HIV-1 envelope proteins are largely mediated via human CD5+ B cells. Immunology 2011; 134: 419-433.
56. Rongvaux A, Willinger T, Martinek J, et al., Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 2014; 32: 364-372.
57. Rathinam C, Poueymirou WT, Rojas J, et al., Efficient differentiation and function of human macrophages in humanized CSF-1 mice. Blood 2011; 118: 3119-3128.
58. Rongvaux A, Willinger T, Takizawa H, et al., Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo. Proc Natl Acad Sci USA 2011; 108: 2378-2383.
59. Willinger T, Rongvaux A, Takizawa H, et al., Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. Proc Natl Acad Sci USA 2011; 108: 2390-2395.
60. Billerbeck E, Barry WT, Mu K, et al., Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rgamma(null) humanized mice. Blood 2011; 117: 3076-3086.
61. Covassin L, Laning J, Abdi R, et al., Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rgamma(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: A mouse model of human allogeneic graft-versus-host disease. Clin Exp Immunol 2011; 166: 269-280.
62. Takagi S, Saito Y, Hijikata A, et al., Membrane-bound human SCF/KL promotes in vivo human hematopoietic engraftment and myeloid differentiation. Blood 2012; 119: 2768-2777.
63. Brehm MA, Shultz LD, Luban J, et al., Overcoming current limitations in humanized mouse research. J Infect Dis 2013; 208 (suppl 2): S125-130.
64. Lan P, Tonomura N, Shimizu A, et al., Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 2006; 108: 487-492.
65. Melkus MW, Estes JD, Padgett-Thomas A, et al., Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 2006; 12: 1316-1322.
66. Vatakis DN, Koya RC, Nixon CC, et al., Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci USA 2011; 108: E1408-1416.
67. Vatakis DN, Bristol GC, Kim SG, et al., Using the BLT humanized mouse as a stem cell based gene therapy tumor model. J Vis Exp 2012: e4181.
68. Ren G, Zhao X, Wang Y, et al., CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFalpha. Cell Stem Cell 2012; 11: 812-824.
69. Addadi Y, Moskovits N, Granot D, et al., p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res 2010; 70: 9650-9658.
70. Loessner D, Holzapfel BM, Clements JA,. Engineered microenvironments provide new insights into ovarian and prostate cancer progression and drug responses. Adv Drug Deliv Rev 2014; 79-80: 193-213.
71. Shiozawa Y, Pedersen EA, Havens AM, et al., Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011; 121: 1298-1312.
72. Hanahan D, Weinberg RA,. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
73. Hutmacher DW,. Biomaterials offer cancer research the third dimension. Nat Mater 2010; 9: 90-93.
74. Clark AK, Taubenberger AV, Taylor RA, et al., A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer. Biomaterials 2013; 34: 4777-4785.
75. Kaemmerer E, Melchels FP, Holzapfel BM, et al., Gelatine methacrylamide-based hydrogels: An alternative three-dimensional cancer cell culture system. Acta Biomater 2014; 10: 2551-2562.
76. Sieh S, Taubenberger AV, Rizzi SC, et al., Phenotypic characterization of prostate cancer LNCaP cells cultured within a bioengineered microenvironment. PLoS One 2012; 7: e40217.
77. Sieh S, Taubenberger AV, Lehman ML, et al., Paracrine interactions between LNCaP prostate cancer cells and bioengineered bone in 3D in vitro culture reflect molecular changes during bone metastasis. Bone 2014; 63: 121-131.
78. Taubenberger AV,. In vitro microenvironments to study breast cancer bone colonisation. Adv Drug Deliv Rev 2014; 79-80C: 135-144.
79. Hirt C, Papadimitropoulos A, Mele V, et al., "In vitro" 3D models of tumor-immune system interaction. Adv Drug Deliv Rev 2014; 79-80: 145-154.
80. Feder-Mengus C, Ghosh S, Weber WP, et al., Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes. Br J Cancer 2007; 96: 1072-1082.
81. Fischer K, Hoffmann P, Voelkl S, et al., Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007; 109: 3812-3819.
82. Ghosh S, Rosenthal R, Zajac P, et al., Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen. Ann Surg 2005; 242: 851-857, discussion 858.
83. Dangles-Marie V, Richon S, El-Behi M, et al., A three-dimensional tumor cell defect in activating autologous CTLs is associated with inefficient antigen presentation correlated with heat shock protein-70 down-regulation. Cancer Res 2003; 63: 3682-3687.
84. Gottfried E, Kunz-Schughart LA, Ebner S, et al., Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 2006; 107: 2013-2021.
85. Ranga A, Gobaa S, Okawa Y, et al., 3D niche microarrays for systems-level analyses of cell fate. Nat Commun 2014; 5: 4324.
86. Hesami P, Holzapfel B, Taubenberger A, et al., A humanized tissue-engineered in vivo model to dissect interactions between human prostate cancer cells and human bone. Clin Exp Metastasis 2014: 1-12.
87. Holzapfel BM, Wagner F, Loessner D, et al., Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. Biomaterials 2014; 35: 4108-4115.
88. Thibaudeau L, Taubenberger AV, Holzapfel BM, et al., A tissue-engineered humanized xenograft model of human breast cancer metastasis to bone. Dis Model Mech 2014; 7: 299-309.
89. Parmar H, Cunha GR,. Epithelial-stromal interactions in the mouse and human mammary gland in vivo. Endocr Relat Cancer 2004; 11: 437-458.
90. Nicolini FE, Cashman JD, Hogge DE, et al., NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration. Leukemia 2004; 18: 341-347.
91. Lee J, Li M, Milwid J, et al., Implantable microenvironments to attract hematopoietic stem/cancer cells. Proc Natl Acad Sci USA 2012; 109: 19638-19643.
92. Groen RW, Noort WA, Raymakers RA, et al., Reconstructing the human hematopoietic niche in immunodeficient mice: Opportunities for studying primary multiple myeloma. Blood 2012; 120: e9-e16.